Evidence map›Paper›PMID 35926816›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2022

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

D J McGrail, P G Pilié, N U Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, A B Heimberger, N T Ueno and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

D J McGrailCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, USA; Lerner Research Institute, Cleveland Clinic, Cleveland. Electronic address: mcgraid@ccf.org.
P G PiliéDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
N U RashidDepartment of Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
L VoorwerkDepartment of Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
M SlagterDepartment of Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Oncode Institute, Utrecht, the Netherlands.
M KokDepartment of Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
E JonaschDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M KhasrawDepartment of The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
A B HeimbergerDepartment of Neurological Surgery, Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, USA.
N T UenoDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
R FerrarottoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J T ChangDepartment of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, Houston, USA.
S-Y LinDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Funding

Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesR00CA240689 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCGRAIL, DANIEL JAMES · 2022 to 2024
$747k
NCI NIH HHS R00 CA240689
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasmsBiomarkers, TumorHumansImmune Checkpoint InhibitorsMutationBiomarkers, TumorImmune Checkpoint Inhibitors

Identifiers

PMID35926816
PMCPMC10325933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.